Nasus Pharma Announces Clinical Data Demonstrating Efficacy of Taffix, Intranasal Antiviral Protection Against Common Cold and Upper Respiratory Infection

NP-003 study terminated early with high significance in reducing viral infection. TEL AVIV , Israel, Nov. 24, 2021 /PRNewswire/ -- Nasus Pharma a privately held clinical-stage biopharmaceutical

Related Keywords

Bulgaria ,United States ,Canada ,Israel ,America ,Barbaraj Mann ,Ella Mendelson ,H Hypromellose Taffix ,Nasus Pharma ,Micha Gladnikoff ,Prnewswire Nasus Pharma ,Megiddo Dalia ,G Brett Moreau ,Kostenloser Wertpapierhandel ,Yaron Drori ,Klang Shmuel ,Dalia Megiddo ,Michal Mandelboim ,Naparstek Yaakov ,Udi Gilboa ,Nasus Pharma Ltd ,Biomedical Research ,Common Cold ,Upper Respiratory Infection ,Upper Respiratory Infections ,Dalia Megiddo Chief Executive Officer ,Executive Chairman ,Upper Respiratory ,South America ,Middle East ,Intranasal Naloxone ,Intranasal Epinephrine ,Lapidot Tair ,Expert Review ,Anti Infective Therapy ,Tair Lapidot ,Taffix Nasal Powder ,Effective Barrier ,Tech Res ,Nofar Atari ,Taffix Nasal Powder Spray Forms ,Effective Barrier Against Infectious New Variants ,Nasus ,Dharma ,Nnounces ,Linical ,Data ,Emonstrating ,Efficacy ,Taffix ,Intranasal ,Antiviral ,Protection ,Against ,Common ,Gold ,Supper ,Espiratory ,Infection ,